RODMAN&RENSHAW Upgrades INmune Bio (NASDAQ:INMB) to “Strong-Buy”

RODMAN&RENSHAW upgraded shares of INmune Bio (NASDAQ:INMB) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

Several other equities research analysts also recently weighed in on INMB. Alliance Global Partners started coverage on INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 price target on the stock. Rodman & Renshaw began coverage on INmune Bio in a report on Tuesday. They set a “buy” rating and a $23.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.75.

INmune Bio Trading Up 1.4 %

Shares of NASDAQ INMB opened at $8.02 on Tuesday. INmune Bio has a 52 week low of $4.32 and a 52 week high of $14.74. The business’s 50 day moving average price is $5.44 and its 200 day moving average price is $6.04.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same quarter last year, the firm earned ($0.48) EPS. On average, sell-side analysts expect that INmune Bio will post -2.24 EPS for the current fiscal year.

Institutional Investors Weigh In On INmune Bio

Institutional investors have recently modified their holdings of the business. Financial Advocates Investment Management raised its holdings in INmune Bio by 14.8% in the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after purchasing an additional 2,000 shares during the period. Jane Street Group LLC purchased a new stake in shares of INmune Bio in the third quarter valued at approximately $79,000. Sanctuary Advisors LLC acquired a new position in shares of INmune Bio during the 3rd quarter worth approximately $113,000. Barclays PLC lifted its position in shares of INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after buying an additional 24,906 shares in the last quarter. Finally, Fermata Advisors LLC lifted its position in shares of INmune Bio by 10.0% during the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock valued at $219,000 after buying an additional 4,267 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors and hedge funds.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.